Clinical trials: Pigmentary Glaucoma
Glaucoma, Open Angle
Comparison of Effect of Postoperative Cyclosporine A 2% Ophthalmic Emulsion and Betamethasone Eye Drop on Surgical Success of Trabeculectomy Procedure
Glaucoma is one of the leading causes of blindness worldwide and trabeculectomy is the most commonly performed operation to slow-down the disease progression.
- Trial name
- BCATS (NCT02114073)
- Testing
- Cyclosporine, Betamethasone
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Mashhad University of Medical Sciences
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
To investigate safety, efficacy, and the dose-response relationship of DE-104 in lowering intraocular pressure in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00868894
- Testing
- DE-104 medium concentration, DE-104 high concentration, 0.005% latanoprost
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Santen Inc.
Open Angle Glaucoma
MINIject 636 in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications
The study will evaluate the efficacy and safety of MINIject 636 and IOP lowering effects with or without glaucoma medications. The procedure will be a stand-alone surgery.
- Trial name
- NCT03374553
- Testing
- MINI DO636, MINI SO636
- Where
- 3 sites in Colombia, India and 1 more
- Volunteers
- 52 people
- Sponsor
- iSTAR Medical
Open-Angle Glaucoma
Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients
Vasoactivity of topical drugs may be of prognostic relevance in glaucoma. There is very little information for a major class, the prostaglandin analogues with regard to this aspect.
- Trial name
- NCT00308945
- Testing
- travoprost 0.004% (drug), latanoprost 0.005% (drug)
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- University Hospital, Basel, Switzerland
Primary Open-Angle Glaucoma (POAG)
Personalized Mobile Reminders for Medication Adherence and Intraocular Pressure Control in Primary Open-Angle Glaucoma
This study evaluates whether a personalized mobile reminder program improves treatment adherence and clinical outcomes in adults with primary open-angle glaucoma (POAG) using topical antiglaucoma eye drops.
- Trial name
- M-GLAUCO (NCT07480577)
- Testing
- Digital Reminder Intervention
- Volunteers
- 84 people
- Sponsor
- Sakarya Yenikent State Hospital
Glaucoma
Clinical Evaluation of Efficacy of SLT to Topical Medication in Lowering IOP
The purpose of this study is to compare Selective laser trabeculoplasty (SLT) and topical medications for initial treatment of open-angle glaucoma /Ocular Hypertension based on intraocular pressure reduction, treatment side…
- Trial name
- NCT01639807
- Testing
- Latanoprost, SLT
- Where
- India
- Volunteers
- 600 people
- Sponsor
- Aurolab
Glaucoma, Open-Angle, Ocular Hypertension
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00051142
- Testing
- Travoprost, Latanoprost
- Where
- United States
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation
The objective of this study is to investigate the pharmacodynamics (as expressed in intraocular pressure [IOP]) of two formulations of tafluprost 0.0015% eyedrops (preserved and unpreserved) in patients with open-angle glaucoma…
- Trial name
- NCT00918346
- Testing
- Tafluprost 0.0015%
- Where
- 3 sites in Finland, Germany
- Volunteers
- 43 people
- Sponsor
- Santen Oy
Primary Open-angle Glaucoma and Ocular Hypertension
Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6
This is a randomized, double-masked, parallel-group, multi-center study. Subjects diagnosed with POAG or OHT who meet eligibility criteria at Visit 1 (Screening) will wash out their current topical IOP lowering medication(s), if…
- Trial name
- NCT03858894
- Testing
- DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
- Where
- 13 sites in United States
- Volunteers
- 98 people
- Sponsor
- Santen Inc.
Primary Open Angle Glaucoma or Ocular Hypertension
A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study
The purposes of this study are to investigate the effect of intraocular pressure lowering efficacy and safety of DE-117 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension who are…
- Trial name
- NCT02822742
- Testing
- DE-117 ophthalmic solution, Latanoprost ophthalmic solution 0.005%
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open-angle Glaucoma
PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)
Objectives: To evaluate the non-inferiority in the intraocular pressure decrease of the preservative-free ophthalmic solution PRO-122, manufactured by Laboratorios Sophia S.A.
- Trial name
- PRO-122LATAM (NCT03193333)
- Testing
- PRO-122, Timolol eye drops, Dorzolamide-Timolol Ophthalmic
- Where
- 2 sites in Colombia, Mexico
- Volunteers
- 51 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Glaucoma and Ocular Hypertension
Prospective,Randomized,Controlled Study to Assess Efficacy,Safety, and Tolerability of SLT vs. PLT in Patients With POAG
A prospective, randomized, controlled study to assess efficacy, safety, and tolerability of selective laser trabeculoplasty vs. pattern laser trabeculoplasty in patients with open-angle glaucoma.
- Trial name
- NCT02231515
- Testing
- Selective laser trabeculoplasty (SLT), Pattern laser trabeculoplasty (PLT)
- Where
- Switzerland
- Volunteers
- 29 people
- Sponsor
- University Hospital, Geneva
Open-Angle Glaucoma, Ocular Hypertension
A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
The purpose of this study was to describe the ocular discomfort immediately upon instillation of Brinzolamide 1%/Brimonidine 0.2% Tartrate Ophthalmic Suspension, Brinzolamide 1% Ophthalmic Suspension, and Brimonidine Tartrate…
- Trial name
- NCT01426867
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2%
- Volunteers
- 103 people
- Sponsor
- Alcon Research
Open-angle Glaucoma (OAG), Ocular Hypertension
Travoprost Five Day Posology Study
The purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.
- Trial name
- NCT01114893
- Testing
- Travoprost 0.004%, Travoprost Vehicle, Travoprost (Groups A, B and C)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01217606
- Testing
- bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy), Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
- Where
- Brazil
- Volunteers
- 185 people
- Sponsor
- Allergan
Open-Angle Glaucoma, Ocular Hypertension
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT04285580
- Testing
- Bimatoprost SR, LUMIGAN
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- AbbVie
Glaucoma, Glaucoma, Open Angle
SOLX Titanium Sapphire Laser for Trabeculoplasty
Use of the Titanium Sapphire laser for laser trabeculoplasty to reduce intraocular pressure in patients with poorly controlled intraocular pressure on maximally tolerated medical therapy or prior failed laser trabeculoplasty.
- Trial name
- NCT00145535
- Testing
- SOLX Titanium Sapphire Laser (TiSaLT), Argon Laser Trabeculoplasty (ALT)
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 120 people
- Sponsor
- SOLX, Inc.
Glaucoma
Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.
- Trial name
- NCT00966940
- Testing
- Travoprost 0.004% ophthalmic solution (TRAVATAN), Tafluprost 0.0015% ophthalmic solution
- Volunteers
- 51 people
- Sponsor
- Alcon Research
Glaucoma Open-Angle Primary, Ocular Hypertension
Open-Label Study of Safety of H1337 in Healthy Volunteers
The trial will evaluate the safety of one dose regimen of H-1337 [1% twice daily (b.i.d.)] in both eyes in healthy volunteers.
- Trial name
- NCT06572397
- Testing
- H-1337 1.0%
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- D. Western Therapeutics Institute, Inc.
Primary Open Angle Glaucoma
African Descent and Glaucoma Evaluation Study
According to the National Eye Institute, Glaucoma affects about three million Americans. Among Blacks in the United States, open- angle glaucoma is the leading cause of irreversible visual loss.
- Trial name
- ADAGES (NCT00221923)
- Where
- 3 sites in United States
- Volunteers
- 1,540 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego